Ground-breaking new Danish research has shown that the current scientific description of the human cell cycle needs to be revised. These findings could also lead to the development of new therapeutic approaches to target an Achilles' heel in different types of cancers.

Scientists from The Scripps Research Institute (TSRI) have deployed a powerful new drug discovery technique to identify an anti-diabetes compound with a novel mechanism of action. The finding, which appeared online ahead of print in Nature Communications, may lead to a new type of diabetes treatment.

Researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) have developed nanoparticles that swell and burst when exposed to near-infrared laser light.

The success of proteasome inhibitors such as VELCADE® (bortezomib) and Kyprolis® (carfilzomib) for the treatment of multiple myeloma has shown that protein homeostasis, which is how cells maintain a balance of protein synthesis and degradation, is a valid pathway for developing drugs to treat cancer. However, attacking the proteasome in solid tumors has not worked to date.

Engineers at the University of Sheffield have discovered that tiny spherical bead-like devices can be guided by physical structures while swimming inside fluids. This opens up a wealth of future possibilities, such as using structures in the body to guide drug delivery, or cracks in rocks to direct environmental clean-up and exploration.

A controversial new paper by James Cook University scientist claims many useful new treatments are being left on the shelf by medical researchers. JCU's Dr David Kault, a medical doctor and mathematician, has examined the way clinical trials of medical treatments are judged.

A new study finds that a component of aspirin binds to an enzyme called GAPDH, which is believed to play a major role in neurodegenerative diseases, including Alzheimer's, Parkinson's and Huntington's diseases. Researchers at the Boyce Thompson Institute and John Hopkins University discovered that salicylic acid, the primary breakdown product of aspirin, binds to GAPDH, thereby stopping it from moving into a cell's nucleus, where it can trigger the cell's death.